PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 12, 2026Harm Reduction Journal0 citationsOpen Access

A continuum of disconnection: the impacts of safer supply program closures on continuity of care, transition, and total loss of service access

View Full Paper
FAFarihah AliCentre for Addiction and Mental HealthASAbigale SprakesLakehead UniversityJMJordan Mende-GibsonCentre for Addiction and Mental Health

Key Points

  • This study examines the effects of Safer Supply Program funding expiration and legislative changes on client wellbeing and access to care.
  • Conducted 30 semi-structured virtual interviews with clients enrolled in Safer Supply Programs prior to funding expiration.
  • Participants recruited through purposive and snowball sampling methods.
  • Data analyzed using Braun and Clarke's reflexive thematic analysis.
  • Participants maintaining access reported clinical stability but experienced anxiety and survivor’s guilt regarding peers lost to care.
  • Those transitioning to new prescribers faced increased surveillance and loss of autonomy in their care.
  • Participants losing access reported severe harm and engagement with unregulated drug markets, with all overdose cases occurring in this group.

Abstract

OBJECTIVE: In March 2025, the expiration of federal pilot funding for Safer Supply Programs (SSPs), combined with restrictive provincial legislative changes to harm reduction service provision in Ontario, disrupted care for thousands of clients at risk of toxic drug poisoning. This study examines the impacts of these changes on client health, social stability, and overdose risk across a continuum of access. METHOD: We conducted 30 semi-structured virtual interviews between September and November 2025 with clients who were enrolled in an SSP prior to March 31, 2025. Participants were recruited via purposive and snowball sampling. Data were analyzed using Braun and Clarke's reflexive thematic analysis to explore experiences across three distinct groups: those who maintained continuity with their prescriber or SSP, those who transitioned to a new prescriber or SSP, and those who lost access entirely. RESULTS: Experiences of harm were directly proportional to the degree of service disconnection. Participants who maintained access (n = 10) retained clinical stability, but reported chronic anxiety and "survivor's guilt" regarding peers who lost care. Participants who transitioned to an alternative prescriber (n = 13) experienced a "medicalization of harm reduction" characterized by increased surveillance (e.g., urine screens, monitored dosing), revoked take-home doses, and the loss of trusted relationships, which undermined their autonomy and stability. Those who lost access entirely (n = 7) experienced significant harms, such as the loss of an entire ecosystem of care (i.e., medication, primary care, and community), an immediate return to the unregulated fentanyl market, and engagement in survival strategies that can lead to criminalization. Notably, 100% (n = 5) of participants who reported an overdose following the policy changes belonged to this group. CONCLUSION: The loss of federal funding for SSPs in Ontario did not solely reduce medication availability; it severed the structural and relational network that supported participants' reintegration into health care services that they previously felt uncomfortable accessing due to stigma, surveillance and mistreatment. Findings reveal a "continuum of disconnection" where the removal of wraparound supports and the reintroduction of punitive clinical practices function as forms of structural violence. Sustainable, low-barrier models are urgently needed to prevent further morbidity and mortality.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Ali et al. (2026) studied this question.

synapsesocial.com/papers/6a02c2fdce8c8c81e9640522https://doi.org/10.1186/s12954-026-01469-z
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Influence of physician networks on the implementation of pharmaceutical alternatives to a toxic drug supply in British Columbia2024 · 17 citations
  2. 2The ‘risk environment’: a framework for understanding and reducing drug-related harm2002 · 1,248 citations
  3. 3Using thematic analysis in psychology2006 · 192,846 citations
  4. 4Canada in breach of ethical standards for clinical trials2013 · 7 citations
  5. 5Barriers and Facilitators to the Use of Medications for Opioid Use Disorder: a Rapid Review2020 · 210 citations